Canaccord lowered the firm’s price target on Nevro to $30 from $57 and keeps a Buy rating on the shares. The firm said its 2023 guidance was raised, though with Q4 guidance slightly below prior expectations as the company remains conservative given macroeconomic concerns and its recent commercial organization changes.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVRO:
- Nevro price target lowered to $14 from $19 at Baird
- Nevro raises FY23 revenue view to $417M-$419M fro $410M-$415M
- Nevro sees Q4 revenue $108M-$110M, consensus $111.34M
- Nevro reports Q3 EPS (65c), consensus (48c)
- Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance
